The Hopewell site is equipped to support clinical-stage development, process-development, and scaleup for cell and gene therapy programs.

An analysis of mpox virus genomes from individuals infected between 2018 and 2023 has provided insights into how the virus ...

Adeno-associated virus Genome and structure Adeno-associated virus (AAV) was first identified as a contaminant of adenovirus in 1965. 26 It is a non-pathogenic parvovirus featuring a single-stranded ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Snyder, R.O. et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8, 1891–1900 (1997).

The adeno-associated virus AVV Vectors In The Gene Therapy in gene therapy market size has witnessed significant growth in recent years and is on a trajectory for further expansion. Market valuation ...

Human adenovirus (HAdV) is a double stranded DNA virus, non-enveloped, that belongs to the Mastadenovirus genus within Adenoviridae family (Wold and Horwitz, 2007). The infections caused by HAdVs may ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) and AstraZeneca (AZN). Read more here.

FDA Approves Merck’s Enflonsia for RSV Prevention in Infants: Enflonsia (clesrovimab-cfor) is a long-acting monoclonal antibody approved to prevent respiratory syncytial virus (RSV) lower respiratory ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...